Patients with recurrent Clostridioides difficile infection (CDI) were less likely to develop bloodstream infections (BSI) if treated with fecal microbiota transplantation (FMT) compared with antibiotics.
Arakoda (tafenoquine; 60 Degrees Pharmaceuticals) has been made available in the US for the prevention of malaria in patients aged ≥18 years.
A review finds that fluconazole is the only commercially available evidence-based option for systemic treatment of cutaneous candidiasis.
The FDA has approved Fetroja for the treatment of complicated urinary tract infections.
The FDA has granted QIDP designation and Fast Track designation to ATM-AVI for treatment of complicated intra-abdominal infections and more.
The FDA has granted Breakthrough Therapy designation to olorofim for the treatment of invasive mold infections.
For infections with Mycoplasma genitalium, resistance-guided therapy using doxycycline followed by azithromycin or moxifloxacin led to high levels of microbiologic cure and low levels of de novo resistance, according to data published in Clinical Infectious Diseases. A total of 383 patients who attended Melbourne Sexual Health Centre in Australia between 2017 and 2018 with sexually…
In a large cross-sectional study of patients with chronic hepatitis C virus (HCV) infection, cannabis use was inversely associated with diabetes.
Beneficial changes in microbial composition and functionality with capsular fecal microbiota transplant lead to improved cognition in patients with cirrhosis and recurrent hepatic encephalopathy, according to study data presented at The American Association for the Study of Liver Diseases’ The Liver Meeting 2019, held November 8 to 12 in Boston, Massachusetts. In order to determine…
Scynexis announced positive topline results from the phase 3 VANISH 303 trial of ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC) in women.
